NRx Pharmaceuticals CEO to Deliver Company Update at Wall Street Conference in May 2025
NRx Pharmaceuticals CEO Dr. Jonathan Javitt to present company update at Wall Street Conference in May 2025. Learn about NRX-100 progress and strategic acquisition plans for treating central nervous system disorders.
This news highlights NRx Pharmaceuticals' advancements in developing treatments for central nervous system disorders, including suicidal bipolar depression and chronic pain. The company's presentation at the conference signifies a significant step in its efforts to bring innovative therapies to market.